INVESTOR RELATIONS Zogenix is committed to developing and commercializing transformative therapies to improve the lives of patients and their families living with rare diseases. 02/23/22 ( FY ) Corporate Presentation Recent News View All News 03.28.22 FINTEPLA® (fenfluramine) Oral Solution Now FDA Approved for Treatment of Seizures Associated with Lennox-Gastaut Syndrome (LGS) Continue Reading 03.07.22 UCB Completes Acquisition of Zogenix, Inc. Continue Reading 03.04.22 Zogenix To Present New Long-term Data on FINTEPLA® (fenfluramine) in Lennox-Gastaut Syndrome (LGS) at AAN 2022 Continue Reading